文献速递胸部肿瘤

肿瘤信息血浆ctDNA检测识别高危I期非小细胞肺癌

Identifying Patients With High-Risk Stage I NSCLC Using a Tumor-Informed Plasma ctDNA Assay.
PubMed 文献 · J Thorac Oncol · 2026-02-21

这项前瞻性队列纳入153例临床I期NSCLC患者(75.8%为病理I期),采用肿瘤信息全外显子测序方法RaDaR实时检测血浆ctDNA。术前ctDNA检出率22.4%,与无复发生存期显著相关(HR 3.81,p=0.006);病理I期患者术后均未检出ctDNA。2年RFS为84.2%,术前ctDNA检出者仅69.1%。

要点

  • 术前ctDNA检出率22.4%,与RFS显著相关(HR 3.81,p=0.006)
  • 病理I期患者术后未检出ctDNA,术前ctDNA和浸润性肿瘤大小独立关联RFS
  • 2年RFS总体84.2%,术前ctDNA检出者降至69.1%

核心结论

  • 血浆ctDNA检测在I期NSCLC治疗决策中具有临床可行性。

研究设计与样本

  • 前瞻性队列研究,纳入153例临床I期NSCLC患者,75.8%为病理I期,采用肿瘤信息全外显子测序方法RaDaR实时检测血浆ctDNA。

主要发现

  • 术前ctDNA检出率为22.4%,中位周转时间6周。
  • 术前ctDNA检出与无复发生存期显著相关(HR 3.81,p=0.006)。
  • 病理I期患者术后均未检出ctDNA。
  • 2年RFS总体为84.2%,术前ctDNA检出者为69.1%。
  • 在病理I期NSCLC中,术前ctDNA检出和浸润性肿瘤大小与RFS独立相关。

临床怎么用

  • 可考虑对I期NSCLC患者术前采集血浆行肿瘤信息ctDNA检测以辅助风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Circulating tumor DNA (ctDNA) has emerged as an important prognostic factor in patients with cancer. Management of early stage NSCLC remains challenging with a high rate of disease recurrence. METHODS: In this prospective cohort, 153 patients with clinical stage I NSCLC (75.8% pathologic stage I) underwent real-time plasma ctDNA testing using a tumor-informed whole exome sequencing approach, RaDaR. RESULTS: Preoperative ctDNA was detected in 22.4% of patients (6 wk of median turnaround time) and was significantly associated with recurrence-free survival (RFS) (hazard ratio: 3.81, p = 0.006). No patients with pathologic stage I disease had detectable postoperative ctDNA. The 2-year RFS was 84.2%, with inferior outcomes among patients with preoperative ctDNA detected (69.1%). In pathologic stage I NSCLC, preoperative ctDNA detection and invasive tumor size remained independently associated with RFS. CONCLUSION: Here, we demonstrate the clinical feasibility of plasma ctDNA to inform treatment decision-making in stage I NSCLC. CLINICALTRIALS: gov identifier: NCT05254782.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Feng J, Khan S, Waddell TK, et al. Identifying Patients With High-Risk Stage I NSCLC Using a Tumor-Informed Plasma ctDNA Assay. J Thorac Oncol. 2026. PMID: 41730473. doi:10.1016/j.jtho.2026.103645

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。